Guerbet announced that Novation has awarded a new agreement for Dotarem (gadoterate meglumine) injection. Dotarem injection is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain ...
Tags: Novation, Dotarem injection, Guerbet
PLC Systems, a medical device company, has obtained an approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to initiate a single-arm clinical trial in Japan using its RenalGuard therapy. This approval is based on MHLW's ...
Tags: PLC Systems, Renalguard Therapy
PLC Medical Systems has been granted a new method patent by the US Patent and Trademark Office, titled, 'Patient Hydration Method.' The patent claims cover the use of RenalGuard Therapy and the RenalGuard device to protect patients' ...
Helio System (TF-FA), an investigational equipment developed for use with the Sapien XT Transcatheter Heart Valve, has been deployed successfully in four patients during a feasibility trial of its use in patients with high-risk aortic ...
Tags: Aortic Insufficiency, Medicine
NGAL (neutrophil gelatinase-associated lipocalin) is a novel biomarker for diagnosing acute kidney injury (AKI). Its measurement can detect damage within 2 hrs of occurrence and also shows a proportionate response to injury. This enables ...
Tags: Acute Kidney Injury, kidney damage, AKI
Argutus Medical was chosen as one of ten companies to display their latest product at the Innovators Place™ during the American Society of Nephrology (ASN) Kidney Week 2012. The scientific exposition, which took place from the 1st ...
Tags: AKI Test, Innovators Place, Argutus Medical
CellAegis Devices has obtained Health Canada's investigational testing (ITA) approval to initiate a pilot clinical trial of its noninvasive autoRIC device for remote ischemic conditioning (RIC). The CE-marked device is placed around ...
Tags: Health Canada, ITA, clinical trial, RIC
Abbott has signed an agreement to acquire all global rights to develop and commercialize AP214 from Action Pharma. AP214 is a hormone analogue which is being developed to prevent acute kidney injury associated with major cardiac surgery ...
Tags: AP214, Abbott, Action Pharma
Astute Medical has obtained CE mark for a new risk assessment tool, designed for patients with acute kidney injury (AKI). The new immunoassay test, NephroCheck, enables large and small hospital laboratories to use two newly validated ...